Out­side re­view con­firms top Memo­r­i­al Sloan Ket­ter­ing ex­ec­u­tives flout­ed con­flicts-of-in­ter­est poli­cies — re­port

The up­per ech­e­lons of the Memo­r­i­al Sloan Ket­ter­ing (MSK) Can­cer Cen­ter have been charged with cul­ti­vat­ing a cul­ture of putting prof­its be­fore re­search and pa­tients by per­sis­tent­ly breach­ing con­flict-of-in­ter­est poli­cies in a re­view con­duct­ed by an in­de­pen­dent body.

The re­sults of the re­view — re­port­ed by the New York Times and ProP­ub­li­ca — so­lid­i­fies a sweep­ing in­ves­ti­ga­tion by the two me­dia or­ga­ni­za­tions last year that found var­i­ous top ex­ec­u­tives and board mem­bers from the lead­ing New York-based can­cer re­search and treat­ment cen­ter had prof­it­ed from re­la­tion­ships with drug­mak­ers, oth­er re­search out­fits and cor­po­rate board mem­ber­ships.

In re­sponse to the in­de­pen­dent re­view, MSK on Thurs­day al­so broad­ened its con­flicts-of-in­ter­est pol­i­cy over­haul, in­clud­ing pub­lic dis­clo­sure of physi­cian ties to cor­po­ra­tions and lim­its on work out­side of MSK.

The con­tro­ver­sial rev­e­la­tions com­ing out of Memo­r­i­al Sloan Ket­ter­ing have al­so had an im­pact on oth­er high pro­file can­cer in­sti­tu­tions, in­clud­ing the Boston-based Dana-Far­ber Can­cer In­sti­tute and Seat­tle-based Fred Hutchin­son Can­cer Re­search Cen­ter — both of whose ex­ec­u­tives sit on cor­po­rate boards — and are re­assess­ing their norms re­lat­ed to fi­nan­cial ties, ac­cord­ing to NYT/ProP­ub­li­ca.

José Basel­ga

The NYT/ProP­ub­li­ca re­ports trig­gered the Sep­tem­ber ex­it of MSK chief med­ical of­fi­cer, José Basel­ga, who failed to dis­close the re­mu­ner­a­tions he re­ceived from a spate of bio­phar­ma firms he as­sist­ed — in terms of ar­ti­cles in med­ical jour­nals as well as or­ga­ni­za­tions like AS­CO, where he head­lined ma­jor pre­sen­ta­tions. Basel­ga al­so stepped down from the boards of Bris­tol-My­ers Squibb and Var­i­an Med­ical Sys­tems, on­ly to be hired by As­traZeneca to run the British drug­mak­er’s on­col­o­gy di­vi­sion this Jan­u­ary.

Craig Thomp­son

The re­portage al­so sparked the dis­en­tan­gle­ment of oth­er MSK re­la­tion­ships. MSK CEO Craig Thomp­son in Oc­to­ber re­signed from the boards of Charles Riv­er Lab­o­ra­to­ries and Mer­ck. In Jan­u­ary, the non­prof­it re­search in­sti­tute re­formed its con­flicts-of-in­ter­est pol­i­cy, by ban­ning its top ex­ec­u­tives from serv­ing on cor­po­rate boards of bio­phar­ma com­pa­nies.

The out­side in­ves­ti­ga­tion — con­duct­ed by the law firm De­bevoise & Plimp­ton — found that MSK of­fi­cials  “fre­quent­ly vi­o­lat­ed or skirt­ed their own poli­cies; that hos­pi­tal lead­ers’ ties to com­pa­nies were like­ly con­sid­ered on an ad hoc ba­sis rather than through rig­or­ous vet­ting; and that re­searchers were of­ten un­aware that some se­nior ex­ec­u­tives had fi­nan­cial stakes in the out­comes of their stud­ies,” the NYT/ProP­ub­li­ca re­port pub­lished on Thurs­day said.

Nev­er­the­less, the vi­o­la­tions were not the re­sult of “in­ten­tion­al mis­con­duct” but due to “in­ad­e­quate over­sight and a lack of es­tab­lished pro­to­cols for ex­am­in­ing whether em­ploy­ees’ and ex­ec­u­tives’ af­fil­i­a­tions with cor­po­ra­tions could re­sult in bi­ased re­sults that fa­vored a com­pa­ny’s prod­ucts,” the ar­ti­cle high­light­ed, cit­ing an MSK staff meet­ing held on Thurs­day.

Im­age: Memo­r­i­al Sloan Ket­ter­ing (MSK) Can­cer Cen­ter

Martin Shkreli [via Getty]

Pris­on­er #87850-053 does not get to add drug de­vel­op­er to his list of cred­its

Just days after Retrophin shed its last ties to founder Martin Shkreli, the biotech is reporting that the lead drug he co-invented flopped in a pivotal trial. Fosmetpantotenate flunked both the primary and key secondary endpoints in a placebo-controlled trial for a rare disease called pantothenate kinase-associated neurodegeneration, or PKAN.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

We­bi­nar: Re­al World End­points — the brave new world com­ing in build­ing fran­chise ther­a­pies

Several biopharma companies have been working on expanding drug labels through the use of real world endpoints, combing through the data to find evidence of a drug’s efficacy for particular indications. But we’ve just begun. Real World Evidence is becoming an important part of every clinical development plan, in the soup-through-nuts approach used in building franchises.

I’ve recruited a panel of 3 top experts in the field — the first in a series of premium webinars — to look at the practical realities governing what can be done today, and where this is headed over the next few years, at the prodding of the FDA.

ZHEN SU — Merck Serono’s Senior Vice President and Global Head of Oncology
ELLIOTT LEVY — Amgen’s Senior Vice President of Global Development
CHRIS BOSHOFF — Pfizer Oncology’s Chief Development Officer

A premium subscription to Endpoints News is required to attend this webinar. Please upgrade to either an Insider or Enterprise plan for access. Already have Endpoints Premium? Please sign-in below. You can contact our Subscriptions team at help@endpointsnews.com with any issues.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Hal Barron. GSK

GSK's Hal Bar­ron her­alds their sec­ond pos­i­tive piv­otal for cru­cial an­ti-BC­MA ther­a­py, point­ing to a push for quick OKs in a crowd­ed field

Hal Barron has his second positive round of Phase III data in hand for his anti-BCMA antibody drug conjugate belantamab mafodotin (GSK2857916). And GSK’s research chief says the data paves the way for their drive in search of an FDA approval for treating multiple myeloma.

It’s hard to overestimate the importance of this drug for GSK, a cornerstone of Barron’s campaign to make a dramatic impact on the oncology market and provide some long-lost excitement for the pharma giant’s pipeline. They’re putting this BCMA program at the front of that charge — looking to lead a host of rivals all aimed at the same target.

We don’t know what the data are yet, but DREAMM-2 falls on the heels of a promising set of data delivered 5 months ago for DREAMM-1. There investigators noted that complete responses among treatment-resistant patients rose to 15% in the extra year’s worth of data to look over, with a median progression-free survival rate of 12 months, up from 7.9 months reported earlier. The median duration of response was 14.3 months.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: An em­bold­ened As­traZeneca splurges $95M on a pri­or­i­ty re­view vouch­er. Where do they need the FDA to hus­tle up?

AstraZeneca is in a hurry.

We learned this morning that the pharma giant — not known as a big spender, until recently — forked over $95 million to get its hands on a priority review voucher from Sobi, otherwise known as Swedish Orphan Biovitrum.

That marks another step down on price for a PRV, which allows the holder to slash 4 months off of any FDA review time.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

Brian Kaspar. AveXis via Twitter

AveX­is sci­en­tif­ic founder fires back at No­var­tis CEO Vas Narasimhan, 'cat­e­gor­i­cal­ly de­nies any wrong­do­ing'

Brian Kaspar’s head was among the first to roll at Novartis after company execs became aware of the fact that manipulated data had been included in its application for Zolgensma, now the world’s most expensive therapy.

But in his first public response, the scientific founder at AveXis — acquired by Novartis for $8.7 billion — is firing back. And he says that not only was he not involved in any wrongdoing, he’s ready to defend his name as needed.

I reached out to Brian Kaspar after Novartis put out word that he and his brother Allen had been axed in mid-May, two months after the company became aware of the allegations related to manipulated data. His response came back through his attorneys.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

Why would Am­gen want to buy Alex­ion? An­a­lysts call hot­ly ru­mored takeover un­like­ly, but seize the mo­ment

A rumor that Amgen is closing in on buyout deal for Alexion has sparked a guessing game on just what kind of M&A strategy Amgen is pursuing and how much Alexion is worth.

Mizuho analyst Salim Syed first lent credence to the report out of the Spanish news outlet Intereconomía, which said Amgen is bidding as much as $200 per share. While the source may be questionable, “the concept of this happening doesn’t sound too crazy to me,” he wrote.

FDA asks why No­var­tis took two months to launch for­mal in­ter­nal probe, af­ter AveX­is flagged da­ta ma­nip­u­la­tion

And the plot thickens. Novartis $NVS officials are reportedly now scrambling to explain to the FDA why it took them two months to open an internal investigation into data discrepancies for their $2.1 million gene-therapy for spinal muscular dystrophy — the world’s most expensive drug.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

Build­ing on suc­cess­ful PD-1 pact, Eli Lil­ly li­cens­es di­a­betes drug to Chi­nese part­ners at In­novent

Eli Lilly is expanding its partnership with China’s Innovent in a deal involving a diabetes drug sitting in its Phase I reserves.

The two companies had jointly developed one of China’s first homegrown PD-1 agents, scoring an approval for Tyvyt (sintilimab) late last year for relapsed/refractory classical Hodgkin’s lymphoma. This time around, Lilly is out-licensing a piece of its diabetes pipeline, a leading franchise that has historically produced the top-selling Trulicity and Humalog.

Am­gen, Al­ler­gan biosim­i­lar of Roche's block­buster Rit­ux­an clears an­oth­er US piv­otal study 

Novartis $NVS may have given up, but Amgen $AMGN and Allergan $AGN are plowing ahead with their knockoff of Roche’s blockbuster biologic Rituxan in the United States.

Their copycat, ABP 798, was found to have a clinically equivalent impact as Rituxan — meeting the main goal of the study involving CD20-positive B-cell non-Hodgkin’s lymphoma patients. This is the second trial supporting the profile of the biosimilar. In January, it came through with positive PK results in patients with rheumatoid arthritis.